Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497191 | 0.86 | — | — | |
| SCHEMBL12963923 | 0.86 | ALDH1A1 (0.33) | ALDH1A1POLBHSD11B1EPHX2L3MBTL1 | |
| SCHEMBL6496506 | 0.84 | HSD11B1 (0.34) | ALDH1A1POLBHSD11B1L3MBTL1TSHR | |
| SCHEMBL13416097 | 0.80 | CYP17A1 (0.40) | ALDH1A1HSD11B1EPHX2NAAAGAA | |
| SCHEMBL13416096 | 0.79 | ALDH1A1 (0.38) | ALDH1A1POLBHSD11B1CA2GAA | |
| SCHEMBL6495033 | 0.78 | EPHX2 (0.50) | ALDH1A1POLBHSD11B1EPHX2L3MBTL1 | |
| SCHEMBL16656615 | 0.76 | — | — | |
| SCHEMBL12963916 | 0.76 | GAA (0.32) | ALDH1A1NAAAGAAMAPTXBP1 | |
| SCHEMBL13834238 | 0.75 | EPHX2 (0.49) | ALDH1A1EPHX2TSHRGAAMAPT | |
| SCHEMBL17236485 | 0.75 | NAAA (0.43) | NAAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949615-B2 | Monomer having electron-withdrawing group and process for preparing the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1331216-A1 | MONOMERS HAVING ELECTRON-WITHDRAWING GROUPS AND PROCESSES FOR PREPARING THE SAME | Daicel Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-20030059710-A1 | Monomer having electron-withdrawing group and process for preparing the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030059710-A1 | Monomer having electron-withdrawing group and process for preparing the same | RFC3, RFC2, MAPRE1 | ALDH1A1 1973/4885POLB 680/4885HSD11B1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.